Schizophrenia Trial, Recruiting NCT06957808 Sponsor: King's College London Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT06957808
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 65 who have been diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-5)
  • People whose antipsychotic medication dose has remained the same for at least one month
  • People who have been symptomatically stable with no relapse in the two months before enrolling in the study
  • People who score at least 60 on a standard symptom rating scale called the PANSS (Positive and Negative Syndrome Scale)
  • People who are able to understand the study and give their informed consent to participate

Who may not be able to join:

  • People with a significant other medical or neurological condition, including (but not limited to) HIV, cancer, Lupus, sarcoidosis, autoimmune vasculitis, or a history of bone marrow transplantation
  • People currently taking medications known to interact with the study drug (called DRF), including certain antibiotics, diuretics, anti-inflammatory painkillers, or Lithium, or who have received a live vaccine during the treatment period
  • People for whom DRF is considered medically unsuitable, including those who are pregnant or breastfeeding; women of childbearing potential who are not using an approved form of contraception; people with severe liver problems, moderate kidney problems, or severe active digestive disease; people with a low white blood cell (lymphocyte) count; people with or suspected of having a serious brain infection called PML; or people with risk factors for PML such as previous use of certain immune-suppressing treatments or a current or recent herpes virus infection
  • People with a current dependence on or misuse of substances other than cigarettes
  • People currently assessed as being at high risk of suicide
  • People who have taken part in a clinical trial of an unlicensed medicine within the past 30 days
  • People with any existing or past illness that would make participation unsafe or unsuitable, or anyone for whom an MRI scan would not be safe (for example, due to claustrophobia, a pacemaker, metal implants, or pregnancy)
  • People with a known allergy to any ingredient in DRF

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Katherine Beck, Clinical Lecturer, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience

Phone: (+44)07871777185

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 January 2025
Est. completion
20 January 2027

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

MRS glutathione (GSH) levels in ACC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov